Pediatrix Medical Group, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $1.23B
  • PE -5
  • Debt $19.28M
  • Cash $103.83M
  • EV $1.14B
  • FCF $127.82M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$253.84M
EBIT-$219.49M
ROE-35%
ROA-11%
FCF$127.82M
Equity$732.49M
Growth Stability-492%
PE-4.84
PEG-2.19
PB1.68
P/FCF9.62
P/S0.61
Price/Cash0.08
Debt/Equity0.03
Debt/FCF0.15
Net Margins-9%
Op. Margins-11%
Earnings CAGR-5%
Sales Growth YoY1%
Sales Growth QoQ1%
Sales CAGR-8%
FCF CAGR-16%
Equity CAGR-15%
Earnings Stability0.16
Earnings Growth YoY-9%
Earnings Growth QoQ-113%
Earnings CAGR 5Y2%
Sales CAGR 5Y-6%
FCF CAGR 5Y-17%
Equity CAGR 5Y-6%
Earnings CAGR 3Y2%
Sales CAGR 3Y2%
FCF CAGR 3Y9%
Equity CAGR 3Y-5%
Market Cap$1.23B
Revenue$2.01B
Assets$2.08B
Total Debt$19.28M
Cash$103.83M
Shares Outstanding83.04M
EV1.14B
Earnings Score5%
Moat Score5%
Safety Score67%
Final Score25%
Working Capital155.14M
Current Ratio1.42
Shares Growth 3y-1%
Equity Growth QoQ4%
Equity Growth YoY-24%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment, which is physician services. Mednax generates roughly half of its revenue from the women's and children's services provided, and also roughly half of the company's total revenue is earned in the United States.

SEC Filings

Direct access to Pediatrix Medical Group, Inc. (MD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Pediatrix Medical Group, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Pediatrix Medical Group, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%
Stability 16%
loading chart...

Pediatrix Medical Group, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Pediatrix Medical Group, Inc..

= $459M
012345678910TV
fcf$128M$107M$89M$74M$62M$52M$43M$36M$30M$25M$21M$211M
DCF$97M$74M$56M$42M$32M$24M$19M$14M$11M$8.1M$81M
Value$459M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins13%12%10%9%7%-43%-46%7%3%-3%-9%
ROA-12%11%8%8%-27%3%7%7%0%-11%
ROE-14%12%10%9%-100%-107%15%7%-7%-35%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-3.794.294.038.255.569.9512.34.325.70.15
Debt over Equity0.260.530.630.610.641.172.341.120.740.760.03
Growth Stability---98%82%-492%-----492%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-14%15%9%5%-4%-51%10%3%1%-6%
Earnings YoY growth-6%-3%-1%-16%-658%-47%-116%-49%-191%2%
Equity YoY growth-8%13%11%1%-51%-50%20%-1%-5%-6%
FCF YoY growth--16%18%14%-48%31%-44%-54%87%-26%-17%